Ripretinib

Ripretinib, sold under the brand name Qinlock, is an oral medication used to treat advanced gastrointestinal stromal tumors in adults. It works as a tyrosine kinase inhibitor that blocks the activity of the KIT and PDGFRA kinases, proteins whose mutated forms drive the growth of these tumors. It is indicated as a fourth-line treatment for patients who have already received at least three prior kinase inhibitor therapies, including imatinib. The United States Food and Drug Administration approved ripretinib in May 2020, describing it as the first drug specifically approved in the United States as a fourth-line treatment for advanced gastrointestinal stromal tumor. Australia approved it in July 2020 and the European Union in November 2021. It is developed and marketed by Deciphera Pharmaceuticals, Inc.